GENE ONLINE|News &
Opinion
Blog

2022-08-18| Trials & Approvals

Bluebird Bio’s Zynteglo Becomes First FDA-Approved Gene Therapy For Beta-Thalassemia

by Joy Lin
Share To

The US FDA has approved Bluebird Bio’s Zynteglo (betibeglogene autotemcel) as the country’s first gene therapy for beta-thalassemia, three years after the treatment received the greenlight in Europe. 

Zynteglo has had a bumpy ride, suffering manufacturing issues and a clinical hold which was only lifted last year. Bluebird has since withdrawn the gene therapy from the European market due to a bumpy rollout and failure to find reimbursement. 

Curing Beta-Thalassemia

Beta-thalassemia is a rare genetic blood disease caused by mutations in the beta-globin, which results in little to no hemoglobin production. Patients with the severe form of this disease, also called transfusion-dependent beta-thalassemia, have to rely on regular red blood cell transfusions for life. 

Zynteglo is a one-time lentiviral vector gene therapy that adds working copies of a modified beta-globin gene into the patient’s hematopoietic stem cells (HSCs) to allow them to produce hemoglobin at normal or near normal levels. 

The US approval is based on results from Bluebird’s Phase 3 studies, where 89% of 41 patients receiving the gene therapy achieved transfusion independence. The patients will be followed up to 4 years, and results have been durable as of the last follow-up.  

An Expensive Therapy

Bluebird’s gene therapy will not be cheap, coming in at $2.8 million, which is well above the $1.7 million tagged on after its European approval. While it is designed as a one-time treatment, the treatment process itself will be conducted over several months. 

The company has said it would reimburse health insurers up to 80% of the cost if Zynteglo fails to produce durable transfusion dependence two years after administration. Bluebird is conducting a long-term follow-up study, LTF-303, to monitor patients who have participated in its clinical studies of lentiviral vector gene therapy through 15 years post-treatment.

©www.geneonline.com All rights reserved. Collaborate with us: service@geneonlineasia.com
Related Post
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Orchard Therapeutics’ Gene Therapy for Rare Neurological Disorder Wins FDA Approval
2024-03-20
Wegovy Expands Its Reach: First Weight-Loss Medication Approved to Reduce Cardiovascular Risk
2024-03-11
LATEST
Mechanisms of Allograft Rejection: Insights from Behind the Scenes
2024-04-25
ImmunityBio’s ANKTIVA® Granted FDA Approval: Breakthrough IL-15 Receptor Agonist First-in-Class for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
2024-04-24
Takeda, Astellas, and Sumitomo Mitsui Banking Declare Agreement For Early Drug Discovery Program Incubation in Joint Venture
2024-04-23
Ochre Bio Announces Partnership with Boehringer Ingelheim to Develop Novel Regenerative Treatments for Patients with Advanced Liver Disease
2024-04-22
Earth Day Awareness: Hospitals Embrace Sustainability Efforts
2024-04-22
WHO Raises Alarm: Bird Flu Threat to Humans an ‘Enormous Concern’
2024-04-19
The Legal Battlefield of Weight-Loss Drugs: Eli Lilly and Novo Nordisk on the Defensive
2024-04-18
EVENT
2024-04-27
2024 Biomedical Final Pitch Competition
Room DA1620, Dana Building, Dana-Farber Cancer Institute, 99 Jimmy Fund Way, Boston, MA 02115
Scroll to Top